Condition
Crohn Disease Clinical Trials
Studies of crohn disease, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 437Crohn Disease
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
There are currently three classes of biologic treatments approved in Canada for the management of moderate-to-severe Crohn's disease: anti-tumor necrosis factor [TNF] alpha, anti-integrin, and anti-interleukin [IL]-23 targeted…
- Trial name
- PATHFINDER (NCT05928039)
- Testing
- TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 - Ustekinumab
- Where
- 23 sites in Canada
- Volunteers
- 210 people
- Sponsor
- University of Calgary
Moderately to Severely Active Crohns Disease
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's…
- Trial name
- SIBERITE-2 (NCT06819891)
- Testing
- Afimkibart
- Where
- 208 sites in United States, Argentina and 25 more
- Volunteers
- 425 people
- Sponsor
- Hoffmann-La Roche
Crohn Disease
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.
- Trial name
- MIRIAD (NCT06997965)
- Testing
- Mirikizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Alimentiv Inc.
Inflammatory Bowel Disease, Crohn's Disease
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Background: Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in the digestive tract. Symptoms include stomach pain, diarrhea, and bleeding.
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT07619547
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Crohn's Disease, Ulcerative Colitis (UC)
Online Pain Education for Crohn's Disease and Ulcerative Colitis
Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online pain educations programs among adult patients with inflammatory bowel disease (IBD) who experience chronic…
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
- Trial name
- NCT07671313
- Testing
- Empowered Relief, Living Better with Chronic Pain
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Cedars-Sinai Medical Center
Inflammatory Bowel Diseases (IBD), Crohn Disease
Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel Disease
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refractory, structurally complicated, postoperative, perianal, pouch-related, or psychosocially complex disease.
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease, Colitis, Ulcerative
- Trial name
- DTT-IBD (NCT07877649)
- Testing
- Routine IBD Management and Advanced-Therapy Exposure
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Crohn's Disease
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease.
- Trial name
- NCT06430801
- Testing
- IV Tulisokibart, SC Tulisokibart
- Where
- 499 sites in United States, Australia and 45 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn Disease, Perianal Fistula
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
Crohn's disease is an inflammatory bowel disease characterized by relapses and remissions, causing lesions throughout the digestive tract and accompanied by diarrhea, abdominal pain, and nutritional disorders.
- Conditions
- Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease
- Trial name
- RIS-PERIANAL (NCT07872449)
- Testing
- Risankizumab
- Where
- 4 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Yuki Horio
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
IBS, Ulcerative Colitis, Active
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
- Conditions
- IBS, Ulcerative Colitis, Active, Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms), Healthy Controls
- Trial name
- NCT02421705
- Testing
- Sample collection
- Where
- Belgium
- Volunteers
- 99,999,999 people, healthy volunteers welcome
- Sponsor
- KU Leuven
Completed, with results posted
All 218Crohns Disease
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.
- Trial name
- NCT04397263
- Testing
- Guselkumab
- Where
- 25 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Janssen Pharmaceutical K.K.
Inflammatory Bowel Diseases, Ulcerative Colitis
A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease
This study aims to test the feasibility, acceptability, and preliminary efficacy of a comprehensive self-management (CSM) intervention for people with inflammatory bowel disease (IBD).
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT05651542
- Testing
- Comprehensive Self-Management Intervention, Control
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Washington
Crohn's Disease (CD)
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).
- Trial name
- NCT02782663
- Testing
- ABT-494
- Where
- 61 sites in United States, Belgium and 16 more
- Volunteers
- 107 people
- Sponsor
- AbbVie
Inflammatory Bowel Disease, Crohn's Disease
ENhanced Recovery in CHildren Undergoing Surgery
The institution of perioperative Enhanced Recovery Protocols (ERPs) has been found to decrease hospital length of stay, in-hospital costs, and complications among adult surgical populations but data in pediatric populations are…
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- ENRICH-US (NCT04060303)
- Testing
- Perioperative surgical care
- Where
- United States
- Volunteers
- 597 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Crohn Disease
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy of ustekinumab dosing in inducing clinical remission (Global) and in maintaining clinical remission (US); to evaluate the safety profile and ustekinumab exposure…
- Trial name
- UNITI Jr (NCT04673357)
- Testing
- Ustekinumab
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 101 people
- Sponsor
- Janssen Research & Development, LLC